Determinants of RASistance to anti-epidermal growth factor receptor agents

被引：63

作者：

Baselga, Jose ^{[1
,2
]}

Rosen, Neal ^{[3
]}

机构：

[1] Vall Dhebron Univ Hosp, Barcelona, Spain

[2] Vall Dhebron Inst Oncol, Barcelona, Spain

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 10期

关键词：

D O I：

10.1200/JCO.2007.15.3700

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1582 / 1584

页数：3

共 22 条

[1] Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[2] Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].

Benvenuti, Silvia ;

Sartore-Bianchi, Andrea ;

Di Nicolantonio, Federica ;

Zanon, Carlo ;

Moroni, Mauro ;

Veronese, Silvio ;

Siena, Salvatore ;

Bardelli, Alberto .

CANCER RESEARCH, 2007, 67 (06) :2643-2648

[3] Options available - from start to finish - for obtaining expression data by microarray [J].

Bowtell, DDL .

NATURE GENETICS, 1999, 21 (Suppl 1) :25-32

[4] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer [J].

Cunningham, D ;

Humblet, Y ;

Siena, S ;

Khayat, D ;

Bleiberg, H ;

Santoro, A ;

Bets, D ;

Mueser, M ;

Harstrick, A ;

Verslype, C ;

Chau, I ;

Van Cutsem, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) :337-345

[5]

De Roock W, 2007, ANN ONCOL

[6] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].

Di Fiore, F. ;

Blanchard, F. ;

Charbonnier, F. ;

Le Pessot, F. ;

Lamy, A. ;

Galais, M. P. ;

Bastit, L. ;

Killian, A. ;

Sesboue, R. ;

Tuech, J. J. ;

Queuniet, A. M. ;

Paillot, B. ;

Sabourin, J. C. ;

Michot, F. ;

Michel, P. ;

Frebourg, T. .

BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169

[7] Targeting ras signalling pathways in cancer therapy [J].

Downward, J .

NATURE REVIEWS CANCER, 2003, 3 (01) :11-22

[8] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

[9] COSMIC 2005 [J].

Forbes, S ;

Clements, J ;

Dawson, E ;

Bamford, S ;

Webb, T ;

Dogan, A ;

Flanagan, A ;

Teague, J ;

Wooster, R ;

Futreal, PA ;

Stratton, MR .

BRITISH JOURNAL OF CANCER, 2006, 94 (02) :318-322

[10] A metalloprotease-disintegrin, MDC9/meltrin-γ/ADAM9 and PKCδ are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor [J].

Izumi, Y ;

Hirata, M ;

Hasuwa, H ;

Iwamoto, R ;

Umata, T ;

Miyado, K ;

Tamai, Y ;

Kurisaki, T ;

Sehara-Fujisawa, A ;

Ohno, S ;

Mekada, E .

EMBO JOURNAL, 1998, 17 (24) :7260-7272

← 1 2 3 →